Moteur de recherche d’entreprises européennes
Financement de l’UE (3 852 879 €) : Optimisation des accélérateurs médicaux Hor11/08/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Optimisation des accélérateurs médicaux
Cancer is a major social problem, and it is the main cause of death between the ages 45-65 years. In the treatment of cancer, radio therapy (RT) plays an essential role. RT with hadrons (protons and light ions), due to their unique physical and radiobiological properties, offers several advantages over photons for specific cancer types. In particular, they penetrate the patient with minimal diffusion, they deposit maximum energy at the end of their range, and they can be shaped as narrow focused and scanned pencil beams of variable penetration depth. Although significant progress has been made in the use of particle beams for cancer treatment, an extensive research and development program is still needed to maximize the healthcare benefits from these therapies. The Optimization of Medical Accelerators (OMA) is the aim of the here-proposed European Training Network, in line with the requirements of the EC’s Medical Exposure Directive. OMA joins universities, research centers and clinical facilities with industry partners to address the challenges in treatment facility design and optimization, numerical simulations for the development of advanced treatment schemes, and in beam imaging and treatment monitoring. The proposed R&D program ranges from life sciences (oncology, cell and micro biology and medical imaging.), physics and accelerator sciences, mathematics and IT, to engineering. It is hence ideally suited for an innovative training of early stage researchers. By closely linking all above research areas, OMA will provide an interdisciplinary education to its Fellows. This will equip them with solid knowledge also in research areas adjacent to their core research field, as well as with business competences and hence give them a perfect basis for a career in research.
| Clatterbridge Cancer Centre | ? |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | 247 873 € |
| AMSTERDAM SCIENTIFIC INSTRUMENTS B.V. | 255 374 € |
| EBG Medaustron GmbH | 255 934 € |
| Fondazione Centro Nazionale Di Adroterapia Oncologica | 535 979 € |
| GSI HELMHOLTZZENTRUM FUR SCHWERIONENFORSCHUNG GmbH | 249 216 € |
| Ion Beam Applications SA | 236 640 € |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 249 216 € |
| ORGANISATION EUROPEENNE POUR LA RECHERCHE NUCLEAIRE | 265 227 € |
| PAUL SCHERRER INSTITUT | 265 227 € |
| The University of Liverpool | 273 288 € |
| The University of Manchester | 273 288 € |
| Universidad de Sevilla | 247 873 € |
| University College London | 272 756 € |
| VIALUX MESSTECHNIK + BILDVERARBEITUNG GmbH | 224 987 € |
https://cordis.europa.eu/project/id/675265
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Clatterbridge Cancer Centre, Birkenhead, Royaume Uni.